Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial
Journal for ImmunoTherapy of Cancer · 2024
DOI: 10.1136/jitc-2024-009662 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Bixia Tang und 22 weiteren Autor:innen. Beteiligte Einrichtung: Peking University Cancer Hospital & Institute, Beijing, China. Hauptthemen laut MEDLINE: Melanoma, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Nona Biosciences (Suzhou) Co. Ltd.
Abstract (Originalsprache)
Background
HBM4003 is a novel anti-CTLA-4 heavy chain-only antibody, designed to enhance Treg ablation and antibody-dependent cell-mediated cytotoxicity while ensuring a manageable safety profile. This phase I trial investigated the safety, pharmacokinetics, immunogenicity and preliminary efficacy of HBM4003 plus with anti-PD-1 antibody toripalimab in patients with advanced solid tumors, especially focusing on melanoma.
Methods
The multicenter, open-label phase I trial was divided into two parts: dose-escalation phase (part 1) and dose-expansion phase (part 2). In part 1, HBM4003 was administered at doses of 0.03, 0.1, 0.3 mg/kg in combination with toripalimab with fixed dosage of 240 mg every 3 weeks. The recommended phase II dose (RP2D) was used in the expansion phase. Primary endpoints were safety and RP2D in part 1 and objective response rate (ORR) in part 2. Biomarkers based on cytokines and multiplex immunofluorescence staining were explored.
Results
A total of 40 patients received study treatment, including 36 patients treated with RP2D of HBM4003 0.3 mg/kg plus toripalimab 240 mg every 3 week. 36 participants (90.0%) experienced at least one treatment-related adverse event (TRAE), of which 10 (25.0%) patients experienced grade ≥3 TRAEs and 5 (12.5%) experienced immune-mediated adverse events (irAEs) with maximum severity of grade 3. No grade 4 or 5 irAEs occurred. Efficacy analysis set included 32 melanoma patients treated with RP2D and with available post-baseline imaging data. The ORRs of anti-PD-1/PD-L1 treatment-naïve subgroup and anti-PD-1/PD-L1 treatment-failed subgroup were 33.3% and 5.9%, respectively. In mucosal melanoma, the ORR of the two subgroups were 40.0% and 10.0%, respectively. Baseline high Treg/CD4+ratio in the tumor serves as an independent predictive factor for the efficacy of immunotherapy.
Conclusions
HBM4003 0.3 mg/kg plus toripalimab 240 mg every 3 week demonstrated manageable safety in solid tumors and no new safety signal. Limited data demonstrated promising antitumor activity, especially in PD-1 treatment-naïve mucosal melanoma. Trial registration number NCT04727164 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Peking University Cancer Hospital & Institute, Beijing, China.
- Department of Medical Oncology, Fujian Medical University Cancer Hospital, Fuzhou, Fujian, China.
- Department of Head and Neck Oncology, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China.
- Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
- Immunotherapy Department, Henan Cancer Hospital, Zhengzhou, Henan, China.
- Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
ORCID-Profile: Bixia Tang, Meiyu Fang, Chuanliang Cui
Förderung
- Nona Biosciences (Suzhou) Co. Ltd
Zitieren
APA
Tang, B., Chen, Y., Jiang, Y., Fang, M., Gao, Q., Ren, X., Yao, L., Huang, G., Chen, J., Zhang, X., Li, R., Zhao, S., Gao, M., Luo, R., Qi, M., Li, F., Zheng, F., Lee, M., Tao, X., …, & Cui, C. (2024). Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-009662
Vancouver
Tang B, Chen Y, Jiang Y, Fang M, Gao Q, Ren X, et al. Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2024-009662
BibTeX
@article{Tang2024,
author = {Tang, Bixia and Chen, Yu and Jiang, Yu and Fang, Meiyu and Gao, Quanli and Ren, Xiubao and Yao, Li and Huang, Gang and Chen, Jing and Zhang, Xiaoshi and Li, Rongqing and Zhao, Shuai and Gao, Meijuan and Luo, Ruixuan and Qi, Meng and Li, Feng and Zheng, Fei and Lee, Michael and Tao, Xiaolu and Duan, Rong and Guo, Jun and Chi, Zhihong and Cui, Chuanliang},
title = {Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
doi = {10.1136/jitc-2024-009662}
}
EUVIMED